![]() #Agena bioscience san diego trialSABER was employed by Kazuto Nishio, M.D., Ph.D., and colleagues at Kinki University and several Japanese medical centers to profile lung cancer-related gene fusions and rare somatic hotspot mutations that may affect patients' therapeutic responses in a phase III trial of multiple lung cancer drugs. UltraSEEK is intended to enhance the sensitivity of the single-allele base extension reaction (SABER) method for MassARRAY genotyping. #Agena bioscience san diego driverThe first panel made available this year, the UltraSEEK Oncogene Panel, uses 40 nanograms of input DNA to interrogate 26 driver mutations in 12 critical oncogenes. UltraSEEK is the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue circulating plasma and tumor samples. In a separate but related announcement, Agena said it will make available later this year to clinical researchers an online tool for MassARRAY that will enable the designing of custom UltraSEEK panels for ultrasensitive interrogation of low-level mutations. Hixson, Jr., Sequenom’s chairman and CEO. “This sale strengthens our balance sheet, and will enable us to focus exclusively on our Sequenom Laboratories business as we work toward achieving profitability,” stated Harry F. The sale comes almost a year after Sequenom said it would conduct a strategic review of its Bioscience unit, once known as Genetic Analysis. Agena assumed the lease for the Bioscience business in San Diego, as well as liabilities related to Bioscience-but which does not include any portion of Sequenom¹s bank debt or convertible notes outstanding, the buyer said.Īgena said it has retained all of the former Sequenom Bioscience employees, and will keep the business headquartered in San Diego. The company also intends to extend the MassARRAY platform into the in vitro diagnostic market with the IMPACT Dx System, for which it has filed a Premarket 510(k) Notification with the FDA.Īgena agreed to pay Sequenom $31.8 million cash upfront, plus up to $4 million in contingent consideration tied to achieving undisclosed regulatory and sales milestones. It incorporates MALDI-TOF mass spectrometry for highly sensitive and specific interrogation of tens to hundreds of multiplexed genetic biomarkers. MassARRAY has been used in more than 2,000 published research studies, Agena said. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |